Mineralys Therapeutics Inc. (MLYS) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 11% of 52W Range • RSI-14 at 29.9 (OVERSOLD (<32))
20D Institutional Volume Accumulation (±12.5% realized swing band)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While MLYS currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($24.78) and Max Pain ($22.30) forces dealer call-delta covering toward $50.03.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Mineralys Therapeutics Inc. (MLYS) slipped -0.65% to $21.24, trading at 11% of its 52-week range ($18.11 – $47.65). Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.
RADNOR, Pa., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in c
- Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily added to an SGLT2 inhibitor achieved a statistically significant reduction in systolic blood pressure at four weeks - - New hormonal and urinary prote
The Explore-CKD trial evaluated the efficacy and safety of lorundrostat, an aldosterone synthase inhibitor, added to guideline-directed background therapy in 59 participants with uncontrolled hypertension, stage 1 to 3b
In the large, pivotal Phase 3 Launch-HTN trial, lorundrostat achieved similar significant blood pressure reductions in participants with and without CKD, with consistent reductions across Stages 1-3 CKD In participants w
The addition of Ms. Peterson and Mr. Coats brings additional commercial and product launch experience to Mineralys ahead of the December 22 PDUFA target action date for lorundrostatRADNOR, Pa., Oct. 19, 2026 (GLOBE NEWSW
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MLYS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MLYS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Mineralys Therapeutics Inc. (MLYS) ranks #540 by composite RQD confidence (43/100, grade D-) and #275 by equity capitalization ($1.88B). Within this direct 5-issuer industry benchmark cohort, MLYS leads on earnings valuation at N/A trailing P/E, while MLYS leads on capital efficiency and profitability with -28.4% ROIC and — gross margin. ADRX currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with MLYS at 43/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MLYS
ACTIVE
Mineralys Therapeutics Inc. | D- | 43/100 | — | — | -28.4% | -0.65% | $1.88B | Benchmark Subject |
| ZBIO Zenas BioPharma Inc. | D- | 39/100 | — | — | -35.0% | -0.04% | $1.87B | /zbio-vs-mlys → |
| TRAX First Tracks Biotherapeutics Inc. | E | 33/100 | — | — | -35.0% | -1.08% | $1.90B | /trax-vs-mlys → |
| ADRX ADARx Pharmaceuticals Inc. | D+ | 52/100 | — | — | — | -0.56% | $1.91B | /adrx-vs-mlys → |
| BRVE Braveheart Bio Inc. | D | 47/100 | — | — | — | -2.62% | $1.91B | /brve-vs-mlys → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Mineralys Therapeutics Inc. (MLYS) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$154.7M, operating cash flow of -$142.4M, and free cash flow of -$142.4M (+14.4% YoY). On the balance sheet, MLYS closed FY2025 with $661.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$154.7M | -$142.4M | -$142.4M | $661.8M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$177.8M | -$166.3M | -$166.3M | $205.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$71.9M | -$81.2M | -$81.2M | — | — |
As of 2026-11-01, Mineralys Therapeutics Inc. (NASDAQ: MLYS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $21.24 (-0.65% 1D, market cap $1.88B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MLYS ranks #540 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MLYS carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.4%. By comparison, ZBIO (Zenas BioPharma Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $1.87B) and TRAX (First Tracks Biotherapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $1.90B). Among the 5-stock peer group, MLYS leads on earnings multiple (N/A) while MLYS leads on capital efficiency (-28.4% ROIC).
Per MLYS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001933414), Mineralys Therapeutics Inc. generated $0 in revenue, -$154.7M in net income, and -$142.4M in free cash flow against $661.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
MLYS last traded at $21.24 (-0.65% on volume of 2,077,183 shares), positioning the stock -14.29% below its 50-day simple moving average ($24.78) and -21.30% below its 200-day simple moving average ($26.99). Across its 52-week range of $18.11 to $47.65, MLYS sits at the 10.6% percentile with a 14-day RSI of 29.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($18.59 to $23.89).
Why MLYS Stock slipped -0.65% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.